{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:05:33Z","timestamp":1793221533982,"version":"4.5.0"},"reference-count":18,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.1001\/jamainternmed.2018.8351","type":"journal-article","created":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T11:03:45Z","timestamp":1554116625000},"page":"642","source":"Crossref","is-referenced-by-count":136,"title":["Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials"],"prefix":"10.1001","volume":"179","author":[{"given":"Emerson Y.","family":"Chen","sequence":"first","affiliation":[{"name":"Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil K.","family":"Joshi","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland"},{"name":"School of Medicine, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Tran","sequence":"additional","affiliation":[{"name":"School of Medicine, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland"},{"name":"Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland"},{"name":"Center for Health Care Ethics, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"ioi180129r1","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/jnci\/djs527","article-title":"Surrogate endpoint analysis: an exercise in extrapolation.","volume":"105","author":"Baker","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"21","key":"ioi180129r2","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMp1700446","article-title":"Accelerated approval and expensive drugs\u2014a challenging combination.","volume":"376","author":"Gellad","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"ioi180129r3","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41571-018-0066-3","article-title":"Reinforcing the social compromise of accelerated approval.","volume":"15","author":"Gyawali","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"ioi180129r4","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.mayocp.2016.02.012","article-title":"Strength of validation for surrogate end points used in the US Food and Drug Administration\u2019s approval of oncology drugs.","volume":"91","author":"Kim","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"ioi180129r5","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1056\/NEJMp1107201","article-title":"Reputation and precedent in the bevacizumab decision.","volume":"365","author":"Carpenter","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"ioi180129r6","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The Strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses.","volume":"175","author":"Prasad","year":"2015","journal-title":"JAMA Intern Med"},{"key":"ioi180129r7","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ejca.2018.11.012","article-title":"A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology.","volume":"106","author":"Haslam","year":"2019","journal-title":"Eur J Cancer"},{"issue":"11","key":"ioi180129r8","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamainternmed.2017.3601","article-title":"Research and development spending to bring a single cancer drug to market and revenues after approval.","volume":"177","author":"Prasad","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"2","key":"ioi180129r10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support.","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"2","key":"ioi180129r11","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1001\/jamaoncol.2015.0203","article-title":"Evaluating expected costs and benefits of granting access to new treatments on the basis of progression-free survival in non-small-cell lung cancer.","volume":"1","author":"Lakdawalla","year":"2015","journal-title":"JAMA Oncol"},{"issue":"6","key":"ioi180129r12","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","article-title":"A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review.","volume":"4","author":"Beaver","year":"2018","journal-title":"JAMA Oncol"},{"issue":"7","key":"ioi180129r13","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1001\/jamaoncol.2018.0610","article-title":"Fulfillment of postmarketing requirements to the FDA for therapies granted oncology indications between 2011 and 2016.","volume":"4","author":"Zettler","year":"2018","journal-title":"JAMA Oncol"},{"issue":"12","key":"ioi180129r14","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jamainternmed.2015.5868","article-title":"Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals.","volume":"175","author":"Kim","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"1","key":"ioi180129r15","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12916-017-0902-9","article-title":"Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?","volume":"15","author":"Kemp","year":"2017","journal-title":"BMC Med"},{"key":"ioi180129r16","doi-asserted-by":"publisher","first-page":"j4530","DOI":"10.1136\/bmj.j4530","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.","volume":"359","author":"Davis","year":"2017","journal-title":"BMJ"},{"issue":"7","key":"ioi180129r17","doi-asserted-by":"publisher","first-page":"e180264","DOI":"10.1001\/jamaoncol.2018.0264","article-title":"Delays in the publication of important clinical trial findings in oncology.","volume":"4","author":"Qunaj","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"ioi180129r18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1634\/theoncologist.2015-0516","article-title":"Assessing the eventual publication of clinical trial abstracts submitted to a large annual oncology meeting.","volume":"21","author":"Massey","year":"2016","journal-title":"Oncologist"},{"key":"ioi180129r9","unstructured":"US Food and Drug Administration. Hematology\/oncology (cancer) approvals & safety notifications. https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm279174.htm. Accessed February 27, 2019."}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamainternalmedicine\/article-pdf\/179\/5\/642\/17551232\/jamainternal_chen_2019_oi_180129.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T12:23:52Z","timestamp":1557231832000},"score":1,"resource":{"primary":{"URL":"http:\/\/archinte.jamanetwork.com\/article.aspx?doi=10.1001\/jamainternmed.2018.8351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2018.8351","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,1]]}}}